Oncology

NEJM Study Finds Osimertinib Exhibits 18.9 Months Progression-Free Survival vs. 10.2 Months With Standard Treatment for NSCLC Patients

The NEJM published results from a phase III trial showing that osimertinib exhibited longer progression-free survival and could be a new first-line treatment for patients with untreated EGFR-mutated NSCLC.

FDA Warns Patients That Thermogram is No Alternative to Mammogram

The U.S. Food and Drug Administration (FDA) has released a warning reminding patients that thermography should not replace mammography for breast cancer screening.

Adverse Events Caused 81% of Patients to Discontinue TKIs for CML, Study Finds

A new study found that adverse effects were the most common reason for patients with chronic myeloid leukemia to discontinue use of tyrosine kinase inhibitors.

New Combo Therapy Doubles Progression-Free Survival in Metastatic Breast Cancer Patients

A new study found that a combination of everolimus and fulvestrant doubled progression-free survival in these patients compared to fulvestrant alone.

NEW GUIDELINES: Safely Discontinue TKIs for Some CML Patients

Patients can take TKIs for the rest of their lives. But do they need to?

Liquid Biopsy Promising for Monitoring Post-Cystectomy Bladder Cancer

Measuring tumor-specific mutations in blood and urine samples may be useful for monitoring response to treatment and identifying early signs of metastases after radical cystectomy in patietns with advanced bladder cancer, according to researchers.

Cleveland Clinic: The New Patient Experience with Cancer

Nathan Pennell, MD, is a leading authority on the treatment of patients with lung cancer. He and colleagues at Cleveland Clinic are leading the development of new treatment approaches and new strategies to improve patient experience. 

Cost Burden Diminishes Care Quality in Minority Cancer Patients

  • Patients with lung and colorectal cancer and limited financial reserves are more likely to have a higher symptom burden and a decreased quality of life.
  • Patients with lung and colorectal cancer and limited financial reserves are more likely to have a higher symptom burden and a decreased quality of life.
  • Results Among patients with lung and colorectal cancer, 40% and 33%, respectively, reported limited financial reserves.

New Guidelines Endorse Daily Aspirin, Without a Doubt

  • Daily low-dose aspirin appears to be one of the most cost-effective disease, morbidity, and mortality preventatives available.
  • Updated guidelines from U.S. Preventive Services Task Force (USPSTF) call for the use of aspirin to prevent both cardiovascular disease and gastrointestinal cancers.
  • Major medical societies endorse daily aspirin.
  • Long-term use appears necessary; greatest benefit after 7.5 years of use.
  • Cancer and cardiovascular disease are two of the leading killers of Americans.
  • Vast literature now supports the use of daily aspirin to prevent disease.

Cancer Outcomes Influenced by Health Insurance Status

  • Two studies published in Cancer reveal that uninsured and Medicaid-insured patients have worse outcomes than patients with private insurance.
  • In these 2 studies, patients with private insurance had a clear survival advantage
  • Based on SEER data on glioblastoma multiforme outcomes, researchers found that an uninsured patient was 14% more likely to have a shorter survival time than a patient who carried private insurance.
  • A patient insured through Medicaid was 10% more likely to have a shorter survival time.
  • In a study of the outcomes of men diagnosed with testicular cancer, compared with men with private insurance, uninsured men were 88% more likely to die.
  • Men insured through Medicaid were 51% more likely to die of the disease.

Oncologists Are Leading the Effort for Universal HPV Vaccination

  • HPV is thought to be responsible for more than 90% of anal and cervical cancers, 70% of vaginal, vulvar, and oropharyngeal cancers, and 60% of penile cancers.
  • The vaccine against human papillomavirus (HPV) is considered to be nearly universally effective when properly administered.
  • Pediatricians and primary care physicians have been unable to succeed in providing widespread vaccination in preteens and adolescents.
  • Studies show that physician assertion of efficacy is the most effective means of convincing parents to inoculate young patients.

Data on Two New Therapies Offer Hope for Myelofibrosis Therapy

  • Data from ASH and ASCO offer new hope for patients with myelofibrosis.
  • Two new oral multikinase inhibitors mark significant advances.
  • Pacritinib and ruxolitinib demonstrated ability to reduce spleen volume by >35%.
  • Data from PERSIST and COMFORT trials are promising.

 

Olanzapine Prevents Chemotherapy-Induced Nausea and Vomiting

  • All patients received highly emetogenic chemotherapy.
  • Olanzapine in conjunction with other antiemetics was highly effective in reducing both nausea and vomiting in these patients.
  • Olanzapine administration significantly improved patients quality of life and Functional Living Index-Emesis questionnaire scores.

Study Compares 4 Adjuvant Chemotherapies for Resected NSCLC

  • Researchers treated all patients with cisplatin with or without vinorelbine, docetaxel, gemcitabine or pemetrexed.
  • Study examined effects of therapy in patients previously treated with bevacizumab.
  • All patients had non-squamous non-small cell lung cancer.
  • Study was not randomized.

Study Compares 4 Adjuvant Chemotherapies for Resected NSCLC

  • Researchers treated all patients with cisplatin with or without vinorelbine, docetaxel, gemcitabine or pemetrexed.
  • Study examined effects of therapy in patients previously treated with bevacizumab.
  • All patients had non-squamous non-small cell lung cancer.
  • Study was not randomized.